AvalehtBHM0 • FRA
add
BACHEM HOLDING AG
Viimane sulgemishind
72,40 €
Tänane vahemik
72,90 € - 72,90 €
Aasta vahemik
51,25 € - 81,50 €
Turuväärtus
5,16 mld CHF
Keskmine maht
27,00
P/E suhe
-
Dividendimäär
-
Põhibörs
SWX
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (CHF) | dets 2025info | Y/Y muutus |
|---|---|---|
Käive | 191,04 mln | 4,70% |
Põhitegevusega seonduv kulu | 4,65 mln | −61,22% |
Puhastulu | 49,35 mln | 17,36% |
Puhaskasumimarginaal | 25,83 | 12,11% |
Puhaskasum aktsia kohta | — | — |
EBITDA | 63,83 mln | 9,45% |
Tõhus maksumäär | 1,53% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (CHF) | dets 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 30,99 mln | −67,45% |
Kogu vara | 2,11 mld | 9,66% |
Kõik kohustused | 650,41 mln | 22,28% |
Kogu omakapital | 1,46 mld | — |
Emiteeritud aktsiate arv | 74,94 mln | — |
Hinna ja väärtuse suhe P/B | 3,72 | — |
Varade tasuvus | 5,95% | — |
Kapitali tasuvus | 8,26% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (CHF) | dets 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | 49,35 mln | 17,36% |
Põhitegevuse rahakäive | 92,80 mln | 220,31% |
Investeeringute raha | −89,05 mln | −624,68% |
Finantseerimise raha | −2,81 mln | −391,01% |
Raha ja raha ekvivalentide muutus | 923,00 tuh | −94,31% |
Tasuta rahavoog | −43,10 mln | −92,30% |
Teave
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients. The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG.
The head office is in Bubendorf in the canton of Basel-Landschaft. Bachem operates production facilities in Vionnaz, Vista and Torrance, and St Helens, as well as a sales and distribution site in Tokyo.
Bachem is one of the largest manufacturers of peptide-based APIs globally, supplying pharmaceutical and biotechnology companies with products used in both clinical development and commercial therapies.
In recent years, the company has expanded its manufacturing capacity, including new large-scale production facilities in Switzerland and the United States.
At the end of 2025, the company employed 2,511 people, reported revenue of CHF 695.1 million, and net income of CHF 148.8 million. Wikipedia
Tegevjuht
Asutatud
1971
Veebisait
Töötajate arv
2 363